Effects of Tapcom Combination Ophthalmic Solution Switched from Tapros 0.0015% and Timoptol XE 0.5% Solutions

Effects of Tapcom Combination Ophthalmic Solution Switched from Tapros 0.0015% and Timoptol XE 0.5% Solutions - Effects of Tapcom Combination Ophthalmic Solution Switched from Tapros and Timoptol XE Solutions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016885

Enrollment

Registered

2015-03-23

Start date

2015-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angle glaucoma, normal tension glucoma or ocular hypertension

Interventions

Switching from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution to Tapcom combination ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: primary open angle glaucoma, normal tension glucoma or ocular hypertension treatment with concomitant use of Tapros 0.0015%, Timoptol XE 0.5% ophthalmic solution and an anti-glaucoma drug

Exclusion criteria

Exclusion criteria: some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of corneal refractive surgery bronchial asthma or a history of the said disease bronchospasm or severe chronic obstructive pulmonary disease cardiac insufficiency, sinus bradycardia, atrioventricular block (II, or III degree) or cardiogenic shock

Design outcomes

Primary

Measure	Time frame
IOP reduction	—

Countries

Japan

Contacts

Public ContactNobuyuki Shoji

Kitasato University Department of Ophthalmology, School of Medicine

nshoji@kitasato-u.ac.jp042-778-9735

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026